Tenecteplase Thrombolytic Therapy for Acute Ischemic Stroke in China
Launched by HUASHAN HOSPITAL · Oct 9, 2023
Trial Information
Current as of October 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a treatment called Tenecteplase (rhTNK-tPA) for patients who have had an ischemic stroke, which is a type of stroke caused by a blocked blood vessel in the brain. The study aims to see how effective and safe this treatment is when given within 4.5 hours after the stroke symptoms start. The trial is currently recruiting participants, and they are open to people of all ages and genders who meet certain criteria.
To be eligible for the trial, patients must have had an acute ischemic stroke and be suitable for a particular type of treatment known as thrombolysis, which helps dissolve the blood clot. Patients with significant missing information in their medical history won't be included in the study. Those who join can expect to receive the treatment and be monitored closely to gather important data on how well it works and its safety. This trial is important because it could help improve stroke treatment options for patients in real-world settings.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all acute ischaemic stroke patients who met eligibility for thrombolysis with intravenous alteplase or TNK and presenting within 4·5 hours of symptom onset.
- Exclusion Criteria:
- • variables with a missing rate \> 40%
About Huashan Hospital
Huashan Hospital, affiliated with Fudan University in Shanghai, is a leading medical institution renowned for its commitment to innovative research and high-quality patient care. As a prominent clinical trial sponsor, Huashan Hospital leverages its extensive expertise in various medical disciplines to advance the development of new therapies and treatment modalities. The hospital's state-of-the-art facilities and multidisciplinary teams facilitate rigorous clinical investigations, ensuring adherence to ethical standards and regulatory compliance. With a focus on improving patient outcomes, Huashan Hospital actively collaborates with academic and industry partners to drive forward-thinking research initiatives that address critical healthcare challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, China
Patients applied
Trial Officials
Qiang Dong
Principal Investigator
Huashan Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported